Advanced search
Publication Cover
Pharmacogenomics and Personalized Medicine Volume 16, 2023 - Issue
Submit an article Journal homepage
238
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line

Chen Wang1 Department of Urology, The People’s Hospital of SND, Suzhou, People’s Republic of China;2 Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-6022-4714View further author information
ORCID Icon,
Qifeng Cao2 Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Shun Zhang2 Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Hailong Liu2 Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Huangqi Duan2 Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Weimin Xia2 Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ChinaView further author information
,
Haibo Shen2 Department of Urology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1183-6570View further author information
ORCID Icon &
Cheng Wang1 Department of Urology, The People’s Hospital of SND, Suzhou, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 219-228 | Received 30 Nov 2022, Accepted 06 Mar 2023, Published online: 17 Mar 2023

References

  • Szklener K, Chmiel P, Michalski A, Mańdziuk S. New directions and challenges in targeted therapies of advanced bladder cancer: the role of FGFR inhibitors. Cancers. 2022;14(6):1416.
  • van Rhijn BWG, Mertens LS, Mayr R, et al. FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?(†). Eur Urol. 2020;78(5):682–687. doi:10.1016/j.eururo.2020.07.002
  • Wang L, Gong Y, Saci A, et al. Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. 2019;76(5):599–603. doi:10.1016/j.eururo.2019.06.025
  • Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404–423. doi:10.3322/caac.21631
  • Siefker-Radtke AO, Necchi A, Park SH, et al. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a Phase 2 study. Lancet Oncol. 2022;23(2):248–258. doi:10.1016/S1470-2045(21)00660-4
  • Xiao JF, Caliri AW, Duex JE, Theodorescu D. Targetable pathways in advanced bladder cancer: FGFR signaling. Cancers. 2021;13:19. doi:10.3390/cancers13194891
  • Chu T, Zhong R, Zhong H, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. J Thorac Oncol. 2021;16(4):643–652. doi:10.1016/j.jtho.2020.11.026
  • Zhou Z, He H, Wang K, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020;368:6494. doi:10.1126/science.aaz7548
  • Jing W, Wang G, Cui Z, et al. FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance. Cancer Res. 2022;82(1):114–129. doi:10.1158/0008-5472.CAN-21-2362
  • Su Y, Luo B, Lu Y, et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2022;28(4):793–809. doi:10.1158/1078-0432.CCR-21-2241
  • Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039
  • Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.CCR-17-3766
  • Sun Y, Du F, Gao M, et al. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer. Thyroid. 2018;28(11):1455–1461. doi:10.1089/thy.2018.0022
  • Pal SK, Tangen C, Thompson IM, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. doi:10.1016/S0140-6736(21)00152-5
  • Liu S, Qin T, Liu Z, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309. doi:10.1038/s41419-020-2511-3
  • Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-7
  • Fang Y, Tian S, Pan Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121:109595. doi:10.1016/j.biopha.2019.109595
  • Tan G, Lin C, Huang C, et al. Radiosensitivity of colorectal cancer and radiation-induced gut damages are regulated by gasdermin E. Cancer Lett. 2022;529:1–10. doi:10.1016/j.canlet.2021.12.034
  • He H, Yi L, Zhang B, et al. USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway. Int J Biol Sci. 2021;17(10):2417–2429. doi:10.7150/ijbs.54442
  • Jin X, Ma J, Liang X, et al. Pre-instillation of tumor microparticles enhances intravesical chemotherapy of nonmuscle-invasive bladder cancer through a lysosomal pathway. Biomaterials. 2017;113:93–104. doi:10.1016/j.biomaterials.2016.10.036

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.